Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus cCRT in Locally Advanced NSCLC
NCT06448910Phase 2Active, not recruiting
- Sponsor
- Fudan University
- Start
- Jul 2024
- Primary completion
- Oct 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in non-small cell lung cancer (NSCLC), sponsored by Fudan University. Primary endpoints: Objective Response Rate at 3 years and Incidence of Treatment-Related Adverse Events at 3 years. Started Jul 2024; status: active, not recruiting.
02
Drugs
cadonilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06448910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06448910.